Cargando…
Evidence Is Enough?: A Systematic Review and Network Meta-Analysis of the Efficacy of Tamsulosin 0.2 mg and Tamsulosin 0.4 mg as an Initial Therapeutic Dose in Asian Benign Prostatic Hyperplasia Patients
PURPOSE: We compared the efficacy of tamsulosin between 0.2 mg and 0.4 mg in Asian prostatic hyperplasia (BPH) patients using network meta-analysis due to lack of studies with direct comparison. METHODS: The literature search was conducted using the MEDLINE, Embase, and Cochrane Library. Keywords us...
Autores principales: | Kim, Su Jin, Shin, In-Soo, Eun, Sung-Jong, Whangbo, Taeg-Keun, Kim, Jin Wook, Cho, Young Sam, Kim, Joon Chul |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean Continence Society
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5380825/ https://www.ncbi.nlm.nih.gov/pubmed/28361519 http://dx.doi.org/10.5213/inj.1734826.413 |
Ejemplares similares
-
The Authors Reply: Reply on “Evidence Is Enough?: A Systematic Review and Network Meta-Analysis of the Efficacy of Tamsulosin 0.2 mg and Tamsulosin 0.4 mg as an Initial Therapeutic Dose in Asian Benign Prostatic Hyperplasia Patients”
por: Kim, Su Jin, et al.
Publicado: (2017) -
Efficacy and Tolerability of Tamsulosin 0.4 mg in Patients with Symptomatic Benign Prostatic Hyperplasia
por: Chung, Jae-Wook, et al.
Publicado: (2011) -
Letter to the Editor: Commentary on “Evidence Is Enough?: A Systematic Review and Network Meta-Analysis of the Efficacy of Tamsulosin 0.2 mg and Tamsulosin 0.4 mg as an Initial Therapeutic Dose in Asian Benign Prostatic Hyperplasia Patients”
por: Tae, Bum Sik, et al.
Publicado: (2017) -
Beneficial Effect of Increasing the Dose of Tamsulosin to 0.4 mg in Japanese
Patients with Benign Prostatic Hyperplasia
por: Hirose, Yasuhiko, et al.
Publicado: (2011) -
An open-label, prospective interventional study of the tolerability and efficacy of 0.4 mg oral tamsulosin oral controlled absorption system in men with lower urinary tract symptoms associated with benign prostatic hyperplasia who are unsatisfied with treatment with 0.2 mg tamsulosin
por: Yang, Pei-Shan, et al.
Publicado: (2018)